The times they are a-changin': prognostic markers in the new era of BCR-targeting therapies for CLL

Bibliography

• Chiorazzi N, Ferrarini M. Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. Blood 2010;117(6):1781-91
   PubMed Web of Science ®Google Scholar
• Rai KR, Sawitsky A, Cronkite EP, Clinical staging of chronic lymphocytic leukemia. Blood 1975;46(2):219-34
   PubMed Web of Science ®Google Scholar
• Binet JL, Auquier A, Dighiero G, A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48(1):198-206
   PubMed Web of Science ®Google Scholar
• Damle RN, Wasil T, Fais F, Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94(6):1840-7
   PubMed Web of Science ®Google Scholar
• Hamblin TJ, Davis Z, Gardiner A, Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94(6):1848-54
   PubMed Web of Science ®Google Scholar
• Crespo M, Bosch F, Villamor N, ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348(18):1764-75
   PubMed Web of Science ®Google Scholar
• Rassenti LZ, Huynh L, Toy TL, ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004;351(9):893-901
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, Benner A, Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343(26):1910-16
   PubMed Web of Science ®Google Scholar
• Davis RE, Ngo VN, Lenz G, Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010;463(7277):88-92
   PubMed Web of Science ®Google Scholar
• Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352(8):804-15
   PubMed Web of Science ®Google Scholar
• Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood 2004;103(12):4389-95
   PubMed Web of Science ®Google Scholar
• Chen L, Widhopf G, Huynh L, Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002;100(13):4609-14
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Alizadeh AA, Widhopf G, Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001;194(11):1639-47
   PubMed Web of Science ®Google Scholar
• Chu CC, Catera R, Hatzi K, Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA. Blood 2008;112(13):5122-9
   PubMed Web of Science ®Google Scholar
• Catera R, Silverman GJ, Hatzi K, Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation. Mol Med 2008;14(11-12):665-74
   PubMed Web of Science ®Google Scholar
• Binder M, Lechenne B, Ummanni R, Stereotypical chronic lymphocytic leukemia B-cell receptors recognize survival promoting antigens on stromal cells. PLoS ONE 2010;5(12):e15992
   PubMed Web of Science ®Google Scholar
• Guarini A, Chiaretti S, Tavolaro S, BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgV H unmutated chronic lymphocytic leukemia (CLL) cells. Blood 2008;112(3):782-92
   PubMed Web of Science ®Google Scholar
• Coscia M, Pantaleoni F, Riganti C, IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells. Leukemia 2011;25(5):828-37
   PubMed Web of Science ®Google Scholar
• Herishanu Y, Perez-Galan P, Liu D, The lymph node microenvironment promotes B-cell receptor signaling, NF-{kappa}B activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011;117(2):563-74
   PubMed Web of Science ®Google Scholar
• Klein U, Tu Y, Stolovitzky GA, Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001;194(11):1625-38
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Sharman J, Sweetenham J, Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010;115(13):2578-85
   PubMed Web of Science ®Google Scholar
• Burger JA, O'Brien S, Fowler N, The Bruton's Tyrosine Kinase inhibitor, PCI-32765, is well tolerated and demonstrates promising clinical activity in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): an update on ongoing phase 1 studies. Blood 2010;116(21):32a
   Web of Science ®Google Scholar
• Furman RR, Byrd JC, Brown JR, CAL-101, An Isoform-selective inhibitor of phosphatidylinositol 3-Kinase P110{delta}, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 2010;116(21):31a
   Web of Science ®Google Scholar
• Deaglio S, Vaisitti T, Aydin S, In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia. Blood 2006;108(4):1135-44
   PubMed Web of Science ®Google Scholar
• Deaglio S, Vaisitti T, Bergui L, CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival. Blood 2005;105(8):3042-50
   PubMed Web of Science ®Google Scholar
• Deaglio S, Aydin S, Grand MM, CD38/CD31 interactions activate genetic pathways leading to proliferation and migration in chronic lymphocytic leukemia cells. Mol Med 2009;16(3-4):87-91
   PubMed Web of Science ®Google Scholar
• Deaglio S, Vaisitti T, Aydin S, CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential. Blood 2007;110(12):4012-21
   PubMed Web of Science ®Google Scholar
• Richardson SJ, Matthews C, Catherwood MA, ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL). Blood 2006;107(9):3584-92
   PubMed Web of Science ®Google Scholar
• Calissano C, Damle RN, Hayes G, In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia. Blood 2009;114(23):4832-42
   PubMed Web of Science ®Google Scholar
• Chan AC, Iwashima M, Turck CW, Weiss A. ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta chain. Cell 1992;71(4):649-62
   PubMed Web of Science ®Google Scholar
• Wiestner A, Rosenwald A, Barry TS, ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003;101(12):4944-51
   PubMed Web of Science ®Google Scholar
• Chen L, Huynh L, Apgar J, ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. Blood 2008;111(5):2685-92
   PubMed Web of Science ®Google Scholar
• Messmer D, Fecteau JF, O'Hayre M, Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib. Blood 2011;117(3):882-9
   PubMed Web of Science ®Google Scholar
• Zenz T, Frohling S, Mertens D, Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL). Best Prac Res 2010;23(1):71-84
   PubMed Web of Science ®Google Scholar
• Schall TJ, Bacon K, Camp RD, Human macrophage inflammatory protein alpha (MIP-1 alpha) and MIP-1 beta chemokines attract distinct populations of lymphocytes. J Exp Med 1993;177(6):1821-6
   PubMed Web of Science ®Google Scholar
• Krzysiek R, Lefevre EA, Zou W, Antigen receptor engagement selectively induces macrophage inflammatory protein-1 alpha (MIP-1 alpha) and MIP-1 beta chemokine production in human B cells. J Immunol 1999;162(8):4455-63
   PubMed Web of Science ®Google Scholar
• Eberlein J, Nguyen TT, Victorino F, Comprehensive assessment of chemokine expression profiles by flow cytometry. J Clin Invest 2010;120(3):907-23
   PubMed Web of Science ®Google Scholar
• Burger JA, Quiroga MP, Hartmann E, High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood 2009;113(13):3050-8
   PubMed Web of Science ®Google Scholar
• Shaffer AL, Yu X, He Y, BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 2000;13(2):199-212
   PubMed Web of Science ®Google Scholar
• Burger JA, Tsukada N, Burger M, Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000;96(8):2655-63
   PubMed Web of Science ®Google Scholar
• Quiroga MP, Balakrishnan K, Kurtova AV, B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood 2009;114(5):1029-37
   PubMed Web of Science ®Google Scholar
• Sivina M, Hartmann E, Kipps TJ, CCL3 (MIP-1alpha) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood 2011;117(5):1662-9
   PubMed Web of Science ®Google Scholar
• Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 2009;114(16):3367-75
   PubMed Web of Science ®Google Scholar
• Ghia P, Strola G, Granziero L, Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22. Eur J Immunol 2002;32(5):1403-13
   PubMed Web of Science ®Google Scholar
• Patten PE, Buggins AG, Richards J, CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood 2008;111(10):5173-81
   PubMed Web of Science ®Google Scholar
• Bystry RS, Aluvihare V, Welch KA, B cells and professional APCs recruit regulatory T cells via CCL4. Nat Immunol 2001;2(12):1126-32
   PubMed Web of Science ®Google Scholar
• Castellino F, Huang AY, Altan-Bonnet G, Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature 2006;440(7086):890-5
   PubMed Web of Science ®Google Scholar
• Lossos IS, Czerwinski DK, Alizadeh AA, Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004;350(18):1828-37
   PubMed Web of Science ®Google Scholar
• Ponader S, Buggy J, O'Brien S, Bruton's tyrosine kinase inhibitor PCI-32765 abrogates BCR- and nurselike cell-derived activation of CLL Cells in vitro and in vivo. Blood 2010;116(21):26a
   Web of Science ®Google Scholar
• Hoellenriegel J, Meadows SA, Sivina M, The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011;118(13):3603-12
   PubMed Web of Science ®Google Scholar
• Honigberg LA, Smith AM, Sirisawad M, The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 2010;107(29):13075-80
   PubMed Web of Science ®Google Scholar
• Herman SE, Gordon AL, Hertlein E, Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011;117(23):6287-96
   PubMed Web of Science ®Google Scholar
• Lannutti BJ, Meadows SA, Herman SE, CAL-101, a p110{delta} selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011;117(2):591-4
   PubMed Web of Science ®Google Scholar
• Herman SE, Gordon AL, Wagner AJ, Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010;116(12):2078-88
   PubMed Web of Science ®Google Scholar
• de Gorter DJ, Beuling EA, Kersseboom R, Bruton's tyrosine kinase and phospholipase cgamma2 mediate chemokine-controlled B cell migration and homing. Immunity 2007;26(1):93-104
   PubMed Web of Science ®Google Scholar
• Niedermeier M, Hennessy BT, Knight ZA, Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood 2009;113(22):5549-57
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Rabe KG, Kay NE, Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia. Cancer 2010;116(20):4777-87
   PubMed Web of Science ®Google Scholar
• Philippen A, Diener S, Zenz T, SYK carries no activating point mutations in patients with chronic lymphocytic leukaemia (CLL). Br J Haematol 2010;150(5):633-6
   PubMed Web of Science ®Google Scholar
• Brown JR, Levine RL, Thompson C, Systematic genomic screen for tyrosine kinase mutations in CLL. Leukemia 2008;22(10):1966-9
   PubMed Web of Science ®Google Scholar
• Puente XS, Pinyol M, Quesada V, Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011;475(7354):101-5
   PubMed Web of Science ®Google Scholar
• Fabbri G, Rasi S, Rossi D, Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 2011;208(7):1389-401
   PubMed Web of Science ®Google Scholar